Target intelligence / Profile preview

Peptidoglycan precursors with D-alanyl-D-alanine terminus (D-Ala-D-Ala) (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall precursor, Other
01

Overview

Peptidoglycan precursors with a D-alanyl-D-alanine (D-Ala-D-Ala) terminus are essential building blocks in the assembly of the bacterial cell wall, particularly in Gram-positive species (Nature Reviews Microbiology, 2008: https://www.nature.com/articles/nrmicro1825). These precursors, most notably Lipid II, feature a pentapeptide chain ending in the D-Ala-D-Ala dipeptide, which serves as the substrate for transpeptidase enzymes during the cross-linking of the peptidoglycan layer (StatPearls, 2023: https://www.ncbi.nlm.nih.gov/books/NBK459263/). This molecular structure is the specific therapeutic target for glycopeptide antibiotics such as vancomycin and teicoplanin. These drugs bind to the D-Ala-D-Ala terminus through a network of hydrogen bonds, creating a steric block that prevents the incorporation of the precursor into the growing cell wall (PubMed, 2014: https://pubmed.ncbi.nlm.nih.gov/24231350/). This disruption of cell wall synthesis leads to osmotic instability and bacterial cell death. Clinical challenges associated with this target include the emergence of resistant strains, such as Vancomycin-resistant Enterococci (VRE), which modify the terminus to D-alanyl-D-lactate to evade drug binding (NIH, 2019: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604941/).

Other names
D-alanyl-D-alanine terminusLipid II pentapeptidePeptidoglycan pentapeptide terminusD-Ala-D-Ala dipeptide
02

Mechanism of action

Inhibition of peptidoglycan polymerization and cross-linking by binding to the D-alanyl-D-alanine terminus of cell wall precursors

03

Biological functions

OtherBacterial cell wall biosynthesisPeptidoglycan cross-linking
04

Disease associations

Infection
05

Safety considerations

NephrotoxicityOtotoxicityRed man syndrome (infusion reaction)Vancomycin-resistant Enterococci (VRE)Vancomycin-resistant Staphylococcus aureus (VRSA)
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

Minimum Inhibitory Concentration (MIC)VanA geneVanB gene

Beyond the preview

Go deeper on Peptidoglycan precursors with D-alanyl-D-alanine terminus (D-Ala-D-Ala) (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidoglycan precursors with D-alanyl-D-alanine terminus (D-Ala-D-Ala) (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call